# Tyra Biosciences, Inc. (TYRA) Stock Analysis: 48.56% Upside Potential Amid Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/tyra-biosciences-inc-tyra-stock-analysis-48-56-upside-potential-amid-strong-buy-ratings/4121242007
- Published: 2026-02-27T11:35:46+00:00
- Author: Madison Wilson

Tyra Biosciences, Inc. (NASDAQ: TYRA), a pioneering player in the biotechnology 
sector, is capturing investor attention with its remarkable growth potential and
a significant upside forecasted by analysts. With a market capitalization of $1.77
billion, this clinical-stage biotech company is focused on developing precision 
medicines, particularly targeting fibroblast growth factor receptor (FGFR) biology.
Based in Carlsbad, California, Tyra is making strides with its innovative SNÅP platform,
designed to predict genetic alterations for developing oncology therapies and genetically
defined conditions.

Currently priced at $33.18, Tyra Biosciences’ stock has experienced a minor dip 
of 1.32, equating to a 0.04% decrease. Despite this slight setback, the company 
has displayed an impressive 52-week range between $7.06 and $34.50, indicating a
robust upward trajectory. This growth is underscored by the average analyst target
price of $49.29, suggesting a potential upside of 48.56% from its current valuation.

The biotechnology company has captivated the market with its leading product candidate,
TYRA-300, which is undergoing clinical trials for treating metastatic urothelial
carcinoma and other solid tumors. Additionally, TYRA-300 is being developed for 
skeletal conditions, including achondroplasia and other FGFR3-driven genetic syndromes.
Tyra’s pipeline also includes TYRA-200, targeting bile duct and solid tumors, and
TYRA-430, aimed at treating hepatocellular carcinoma. These developments position
Tyra Biosciences as a dynamic entity within the biotech landscape, offering promising
therapeutic solutions.

From a technical standpoint, Tyra’s stock shows a 50-day moving average of $28.91
and a 200-day moving average of $16.93, reflecting its strong upward momentum over
the past year. The Relative Strength Index (RSI) stands at 43.99, suggesting the
stock is neither overbought nor oversold, a neutral position that could indicate
room for future growth. Additionally, the Moving Average Convergence Divergence (
MACD) at 1.21 and a signal line of 0.95 hint at a potential bullish trend.

Despite the lack of traditional financial metrics like P/E, PEG, and Price/Sales
ratios, which are not applicable given its clinical-stage status, Tyra’s valuation
is supported by its innovative pipeline and strategic focus on precision medicine.
The company’s negative EPS of -1.88 and a return on equity of -34.75% are typical
for companies in this development phase, reflecting ongoing investments in research
and development. The free cash flow of -$48.56 million further emphasizes its commitment
to advancing its clinical programs.

Analysts are overwhelmingly positive about Tyra Biosciences’ prospects, with all
11 analysts issuing a “Buy” rating. This unanimous confidence is bolstered by the
absence of “Hold” or “Sell” ratings, highlighting the market’s bullish sentiment
towards Tyra’s growth trajectory. The target price range of $37.00 to $59.62 offers
a broad perspective on the potential valuation of the stock, with the higher end
suggesting significant appreciation potential.

For investors seeking exposure to the biotechnology sector, Tyra Biosciences represents
an intriguing opportunity. Its focus on precision medicine and the development of
targeted therapies positions it at the forefront of innovative healthcare solutions.
As the company progresses with its clinical trials and further develops its pipeline,
Tyra’s stock could offer substantial returns for those willing to embrace the risks
associated with investing in a clinical-stage biotech firm.

Share on:
